The Breast Cancer Cure Blueprint 2012 Report Card.

Hybrid Pharmaceutical, the Genomics Biotech Engineering company, CEO Rose Conrad Ph.D. gives us
The Breast Cancer Cure Blueprint 2012 Report Card. From MD Anderson Galveston TX, Campus Business Wire

Hybrid GenNxeix Breast Cancer Researchers and Scientist are ahead of the curve with several new technologies based on Nanoparticles and Semi Conductors Namely Genomics and treatments.
The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.


The result is that the ability to determine Targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data.

The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00.
The lower cost, along with increasing speed, has led to a huge increase in how much breast Cancer sequencing data is being produced.

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid GenNxeix Researchers Say that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. The heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
Hybrid GenNxeix understands that Hyperthermia gold nanoshell Targeted breast cancer genomics at 40 for high risk women will reduce breast cancer at 60 years of Age. Training Genomics Counselor and Storing DNA Analysis in the cloud will allow Hybrid GenNxeix to say that Chemotherapy will help their breast cancer outcome or if Chemotheraphy and Hyperthermia will extend their life.